Month: January 2024
Second Circuit Highlights Difficulty in Pleading Fraud Claims Involving the Interpretation of Clinical Data
Plaintiffs often file securities fraud claims against pharmaceutical companies alleging that the company misled investors about clinical data, despite the US Food and Drug Administration (FDA) subsequently approving the drug and agreeing with the company’s interpretation. In December 2023, the US Court of Appeals for the Second Circuit affirmed dismissal of […]
Securities Litigation + Enforcement Highlights From Q4 2023
Closing out 2023, Cooley’s securities litigation + enforcement practice continued providing guidance to our clients on recent developments in securities law – with a particular focus during the fourth quarter on Securities and Exchange Commission (SEC) enforcement trends. Below is a roundup of key insights and developments from our team […]